Bladder hyperthrmia in the treatment of vesical papillomatosis

Lunglmayr, G; Czech, K; Zekert, F; Kellner, G.

doi:10.1007/bf02081753

Cited by 11 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…. Initial reports in the literature suggested that perfusion at temperatures up to 45°C were well tolerated by patients and caused no permanent bladder damage (Lunglmayr et al 1973, Hall et al 1974. This was surprising in view of the results of Moritz (1947) and the explanation may be that the whole bladder was not being exposed to the temperature stated.…”

Section: Discussionmentioning

confidence: 58%

Hyperthermic Irrigation of Bladder in Treatment of Transitional Cell Carcinoma: Its Effectiveness in Controlling Persistent Haematuria

1979

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 58%

Hyperthermic Irrigation of Bladder in Treatment of Transitional Cell Carcinoma: Its Effectiveness in Controlling Persistent Haematuria

1979

View full text Add to dashboard Cite

“…The first bladder hyperthermia treatment was attempted in 1972 where Thio-Tepa was used in conjunction with HT up to 44°C for low stage bladde r tumors. 66 Since then, multiple adverse events that include hematuria, UTI, sepsis, stricture, allergic reaction to chemotherapy agent, dysuria, frequency, urgency and incontinence have been reported (Table 3). There was insufficient data to pool for grade 3 or higher adverse events, UTI, sepsis and allergic reaction.…”

Section: Safetymentioning

confidence: 99%

Heated Intravesical Chemotherapy

Tan

Longo

Inman

2020

Urologic Clinics of North America

View full text Add to dashboard Cite

Non-muscle invasive bladder cancer (NMIBC) can be a challenging disease to manage. In recent years, hyperthermia therapy in conjunction with intravesical therapy has been gaining traction as a treatment option. Hyperthermic intravesical chemotherapy is an alternative method of managing NMIBC, especially if BCG might not be available. Trials of intravesical chemotherapy with heat are few and there has been considerable heterogeneity between studies. However, multiple new trials have accrued and high-quality data is on its way. In this review, we discuss the role of combined intravesical hyperthermia and chemotherapy as a novel approach for the treatment of bladder cancer.

show abstract

“…In 1972, Lunglmayr et al (6) first applied hyperthermic therapy to the treatment of bladder tumors. Subsequently, Colombo et al (7) used microwave equipment to locally heat the bladder for intravesical hyperthermic chemotherapy means the advent of this new therapy.…”

Section: Introductionmentioning

confidence: 99%

Hyperthermic Intravesical Chemotherapy Shed New Light on Therapy for NMIBC: A Meta-Analysis

Zhao

2024

TMBLS

View full text Add to dashboard Cite

Background: Non-muscle-invasive bladder cancer accounts for the 75% of bladder cancers but with limited kinds of therapies, especially in the situation that the shortage and high failure rate of intravesical bacillus Calmette-Guérin. There is some evidence that hyperthermic intravesical chemotherapy could enhance the effect of normal intravesical chemotherapy and may be the alternative. Method: To verify the effect of hyperthermic intravesical chemotherapy, we searched three databases including PubMed (Medline), Embase, and Cochrane Library for related studies. The main outcome were the OR (odds ratio) and the survival data. The quality of studies was evaluated by two authors independently using Jadad Scale for prospective studies and Newcastle-Ottawa Scale (NOS) for retrospective studies. Result: In total, 1,900 patients were included in the quantitative evaluation. The meta-analysis demonstrated significant difference in recurrence rate (OR = 0.42, 95%CI = 0.25-0.72, p=0.0015) and RFS (HR = 0.69, 95%CI = 0.54-0.88, p=0.0029) between hyperthermic intravesical chemotherapy with control groups (intravesical bacillus Calmette-Guérin and normal intravesical chemotherapy) but no obvious advantage in OS (HR = 0.84, 95%CI = 0.59-1.19, p=0.7805) and PFS (HR = 0.51, 95%CI = 0.06-4.08, p=0.5285). We separately use way of heat, control therapy, solvent, country and study type to conduct the subgroup analysis for recurrence rate and RFS. Conclusion: Hyperthermic intravesical chemotherapy can enhance the effect of normal intravesical chemotherapy and act as the alternative for intravesical bacillus Calmette-Guérin, and more studies are needed for further analyses.

show abstract

Bladder hyperthrmia in the treatment of vesical papillomatosis

Cited by 11 publications

References 20 publications

Hyperthermic Irrigation of Bladder in Treatment of Transitional Cell Carcinoma: Its Effectiveness in Controlling Persistent Haematuria

Hyperthermic Irrigation of Bladder in Treatment of Transitional Cell Carcinoma: Its Effectiveness in Controlling Persistent Haematuria

Heated Intravesical Chemotherapy

Hyperthermic Intravesical Chemotherapy Shed New Light on Therapy for NMIBC: A Meta-Analysis

Contact Info

Product

Resources

About